Pictures of Lung Nodules: Benign vs. Malignant

Lung nodules show up as small, round or oval white spots on chest CT scans, and the features visible in those images are the primary way radiologists sort harmless spots from potentially cancerous ones. Roughly one in four adults who get a chest CT will have at least one nodule detected, yet the vast majority turn out to be benign. The distinction on imaging comes down to a handful of visual clues: the nodule’s edges, its density, whether it contains calcium, how fast it grows, and where exactly it sits in the lung. Understanding what those features actually look like on a scan can take some of the mystery out of a report that mentions a “pulmonary nodule.”

How Common Lung Nodules Are

Lung nodules are extraordinarily common. A systematic review and meta-analysis pooling data from multiple studies estimated the overall prevalence of pulmonary nodules at about 27%.¹ That means roughly one in every four people who undergo chest CT imaging will have at least one nodule show up. A separate review focusing specifically on incidental findings from non-cancer-related imaging, such as cardiac CT scans, confirmed that nodules are frequently picked up even when nobody was looking for them.² Most of these spots are old granulomas from past infections, small lymph nodes, or benign growths like hamartomas. Only a small fraction end up being cancer, but that small fraction is what makes the imaging features so important to interpret correctly.

Why CT Scans Reveal So Much More Than Chest X-Rays

If you have only seen a chest X-ray, the flat, overlapping shadows make small nodules easy to miss. Standard chest radiography catches fewer than half of lung nodules, with one study putting sensitivity at roughly 46%. Low-dose CT, by contrast, detects nodules with far greater reliability, achieving sensitivity above 90% when certain image-processing techniques are applied.³ That gap explains why someone might have a “clear” chest X-ray and then be told a CT found a nodule. The CT produces thin cross-sectional slices of the chest, letting radiologists examine a nodule’s shape, borders, and internal texture in detail that a flat film simply cannot provide.

What Benign Nodules Tend to Look Like

A nodule that looks reassuring on CT typically has smooth, well-defined edges. Think of a small, round marble floating in lung tissue with a crisp outline. Benign nodules are often uniformly solid and may contain calcification in characteristic patterns: diffuse (the entire nodule is bright white), central (a dense core of calcium), lamellated (rings of calcium like an onion), or “popcorn” (chunky, irregular calcium deposits, classically seen in hamartomas).⁴ These patterns of calcification have historically been treated as strong markers of benign disease. The logic is straightforward: infections like tuberculosis or histoplasmosis heal by leaving a small, calcified scar in the lung, and that scar shows up as a bright, dense spot.

Size matters too. Nodules smaller than 6 mm are overwhelmingly benign. The updated Fleischner Society guidelines, which are the most widely used framework for managing incidental nodules, raised the threshold below which no routine follow-up is needed in low-risk patients to 6 mm, reflecting the very low cancer probability in small nodules.⁵ So if your CT report describes a 4 mm smooth nodule, the odds of it being cancer are vanishingly small.

What Malignant Nodules Tend to Look Like

Cancerous nodules often display features that stand out from the smooth, round benign profile. The most commonly flagged warning sign is spiculation: instead of smooth edges, the nodule has tiny spiky projections radiating outward into the surrounding lung, like a sea urchin. On a CT image, this gives the nodule a “starburst” or “corona radiata” appearance. A study nested within the National Lung Screening Trial found that border definition, concavity, and attachment to a blood vessel were among the most informative visual features for predicting cancer.⁶ Nodules located in the upper lobes of the lung also carried higher odds of malignancy in that analysis, as did nodules found in patients with background emphysema.

Other suspicious signs include irregular shape, a lobulated contour (the surface looks lumpy, like a cluster of bubbles pressed together), and the presence of a “notch” or concavity along the nodule’s edge. None of these features alone proves cancer. A nodule can be spiculated and still turn out to be a scar from an old infection. But when several of these features appear together, radiologists raise their suspicion considerably.

Calcification Is Not Always Reassuring

One of the persistent misconceptions about lung nodule images is that any calcium means the nodule is safe. While certain calcification patterns are indeed strong evidence of a benign process, not all calcium is created equal. Eccentric calcification, where a bright spot of calcium sits off-center within the nodule, can indicate a cancer that has engulfed a preexisting calcified granuloma. Certain cancers, including carcinoid tumors and metastases from bone cancers like osteosarcoma, can produce their own calcification.⁷ The pattern of calcium matters far more than its mere presence. A radiologist seeing popcorn or central calcification can be fairly confident. One seeing eccentric or stippled calcification will keep the nodule on the watchlist.

Ground-Glass and Part-Solid Nodules

Not all nodules look like solid white dots. Some appear as faint, hazy patches, like looking through frosted glass. These are called ground-glass nodules (GGNs). Others are mixed, with a hazy component and a denser solid core, known as part-solid nodules. The visual distinction matters because it tracks closely with the type and aggressiveness of any underlying cancer.

Pure ground-glass nodules that turn out to be malignant are typically adenocarcinoma in situ or minimally invasive adenocarcinoma, both of which are extremely slow-growing and have excellent outcomes after treatment. A retrospective study found that patients with pure ground-glass nodules who underwent surgery had a five-year survival rate of 96%, far exceeding national averages for lung cancer as a whole.⁸ Part-solid nodules, though, deserve more caution. In that same study, nodules with a ground-glass component below 50% had worse survival, closer to fully solid nodules, with a five-year survival rate around 80%. The development of a growing solid component within a previously pure ground-glass nodule is one of the key imaging changes that prompts a biopsy or surgery.

Risk prediction models commonly used in clinical practice, including the Mayo Clinic, Brock, and Herder models, have been found to underestimate the cancer probability in pure ground-glass and part-solid nodules. One study of these nodule types showed an overall malignancy rate above 90%, yet the models’ median risk scores clustered around 10 to 13%.⁹ This is worth knowing because it means a “low risk” score on a subsolid nodule should not by itself provide complete reassurance.

Growth Rate Over Time

One of the strongest ways to distinguish benign from malignant nodules is to compare CT images taken months apart. A nodule that has not changed size in two years is generally considered benign by clinical guidelines. When growth does occur, the speed of that growth, measured as volume doubling time (VDT), provides a further clue.

In a screening-based study, malignant solid nodules that were growing had a median VDT of about 204 days, while growing benign solid nodules had a median VDT of roughly 386 days. Among growing solid nodules, 92% of malignant ones doubled their volume in under 400 days, compared with 58% of benign ones.¹⁰ The practical takeaway: a nodule that is growing quickly is more worrying than one that is creeping, but the overlap between benign and malignant growth rates is real. Some infections and inflammatory processes grow briskly, and some cancers grow slowly. Growth speed narrows the differential but rarely settles the question on its own.

What PET Scans Add to the Picture

When a CT scan raises enough suspicion, a PET scan is often the next step. PET scans measure metabolic activity by tracking how avidly a nodule takes up a radioactive sugar tracer. The result is reported as a standardized uptake value (SUV). A commonly used cutoff of 2.5 has been used to separate benign from malignant nodules, with values above that threshold raising concern for cancer.¹¹

In practice, the relationship between SUV and malignancy is more of a sliding scale than a clean dividing line. A large study of nearly 600 patients found that when the maximum SUV was between 0 and 2.5, there was still a 24% chance the nodule was malignant. When the value fell between 2.6 and 4.0, the probability jumped to 80%, and at 4.1 or above it was 96%.¹² The takeaway is that a “cold” nodule on PET is reassuring but not a guarantee, and a “hot” nodule is highly suspicious but can occasionally reflect an active infection or inflammatory condition like sarcoidosis. PET scans are also less reliable for very small nodules and for the slow-growing ground-glass type, which may not take up enough tracer to register.

How Doctors Estimate Cancer Risk

Rather than relying on any single feature, clinicians use risk prediction models that combine patient factors and imaging findings into an overall probability. The most widely used models include the Mayo Clinic model, the Brock University model, and the Herder model. They differ in the variables they weigh, but all incorporate some combination of patient age, smoking history, nodule size, spiculation, and upper-lobe location.¹³ The Herder model adds PET scan data, making it useful when metabolic information is available. The Brock model factors in the number of nodules and the presence of emphysema.¹⁴

These models give a percentage probability, which then guides the next step. A nodule scored at less than 5% risk might just be watched with a follow-up CT in several months. One scored above 65% will likely go straight to biopsy or surgery. Everything in between enters a gray zone where additional imaging, PET scans, or short-interval follow-up may be recommended. The updated Fleischner guidelines emphasize that morphologic features and patient risk factors should be considered together, not in isolation.¹⁵

When a Biopsy Is Needed and How It Is Done

If imaging and risk scoring cannot confidently rule cancer in or out, a tissue sample is the definitive next step. Two main approaches exist: navigational bronchoscopy, where a thin scope is threaded through the airways to the nodule, and transthoracic needle biopsy, where a needle is inserted through the chest wall under CT guidance. A recent randomized trial comparing the two found that navigational bronchoscopy achieved an accurate diagnosis in about 79% of patients, while transthoracic needle biopsy achieved one in about 74%, making bronchoscopy at least as effective.¹⁶ The major difference was in complications: pneumothorax, a condition where air leaks into the space around the lung, occurred in roughly 28% of needle biopsy patients but only about 3% of bronchoscopy patients. That safety gap is shifting clinical practice toward bronchoscopy-first strategies for many nodules.

Artificial Intelligence and Nodule Classification

AI tools trained on thousands of CT images are increasingly being tested to help radiologists distinguish benign from malignant nodules. A systematic review of deep-learning models reported that these systems typically achieve an area under the curve above 90%, indicating strong discriminative ability.¹⁷ In one external validation, an AI system detected primary lung cancers with about 97% sensitivity and benign nodules with about 94% sensitivity, at roughly one false positive per scan, a performance comparable to or slightly better than radiologists reading the same images.¹⁸

These tools are not replacing human judgment yet. They function as a second reader, flagging nodules the radiologist might have overlooked or giving a probability score that complements the risk models. In resource-limited settings, pairing AI with mobile low-dose CT scanners has shown promise for making lung cancer screening feasible in underserved communities where specialist radiology is scarce.¹⁹

False Alarms and Imaging Artifacts

Sometimes what looks like a nodule is not a nodule at all. One published case involved a man referred for evaluation of what appeared to be multiple subpleural lung nodules scattered throughout both lungs, mimicking metastatic disease. Careful review of the scan revealed that the “nodules” corresponded exactly to folds and thickened areas in the patient’s undershirt, which he had been wearing during the scan.²⁰ Artifacts from clothing, jewelry, or even body habitus can produce spots on CT images that resemble real nodules. Radiologists are trained to check for these, but if you have been asked to come back for a repeat scan “without clothing above the waist,” this is likely why.

The Emotional Weight of a Nodule Finding

Being told you have a lung nodule, even when the doctor says it is probably nothing, can be profoundly unsettling. In a quality improvement study, about 60% of patients with a known pulmonary nodule reported worrying about it at least once a month, and roughly one in five worried daily. Average anxiety scores were nearly 5 out of 10 before any educational intervention.²¹ After patients read a simple fact sheet explaining what nodules are and how common benign findings are, over 80% reported reduced anxiety. The information itself was therapeutic.

Qualitative research paints a more vivid picture of the waiting period. Some patients interpreted the disclosure of a nodule as essentially being told they had lung cancer, and the surveillance period between scans brought feelings of shock, fear, and difficulty coping with uncertainty.²² Patients undergoing nodule surveillance in a Swedish population-based study had nearly four times the odds of reporting anxiety about lung cancer compared with people not under surveillance. This anxiety is worth acknowledging because it is common, understandable, and does not mean the nodule is likely to be cancer. If you are in this position, asking your doctor to walk you through the specific imaging features and the estimated risk percentage can help ground the abstract worry in concrete information.

Screening Disparities and Who Benefits Most

Low-dose CT lung cancer screening is recommended for current and former heavy smokers in certain age ranges, and the evidence is clear that catching cancer at an earlier stage saves lives. But access to screening is far from equal. An analysis using U.S. Preventive Services Task Force criteria found that screening eligibility was much higher among people with lower incomes and less education, reflecting higher smoking rates in those groups, yet these same populations face the steepest barriers to actually getting screened. Achieving full screening compliance was estimated to produce economic value of up to $560 per eligible person and was found to be cost-effective, with roughly a third of the total value attributable to reducing health disparities.²³ A separate cost-effectiveness analysis from New Zealand found that LDCT screening was likely cost-effective for the general population and for Māori specifically, with health gains per capita for Māori women roughly twice those for non-Māori women.²⁴ The images themselves are the same regardless of who lies on the scanner table, but the chance of ever seeing those images depends heavily on geography, income, and access to care.